The Trump administration's plan to route Ebola-exposed U.S. citizens to Kenya, rather than U.S. or European centers, reverses protocols refined during the 2014 West African outbreak when all exposed Americans returned home for treatment in specialized units. This shift overlooks key evidence from an observational NEJM study (2014, n=27 confirmed U.S. cases, no RCT possible due to ethics and rarity) showing 81% survival in domestic biocontainment facilities versus higher mortality risks in lower-resource settings. Original coverage misses how Kenya's strained health infrastructure—documented in WHO post-outbreak reviews—lacks equivalent negative-pressure isolation capacity, potentially amplifying transmission during the 21-day monitoring window. A second CDC observational analysis of quarantine efficacy (2015, sample of 1,200 monitored contacts) found domestic protocols reduced secondary cases by 95%, with no conflicts of interest declared. The policy could reshape travel decisions for aid workers and researchers within months, echoing patterns from prior administrations that prioritized rapid repatriation to maintain public trust. By framing Kenya as an alternative without addressing these gaps, the approach risks politicizing quarantine rather than grounding it in transmission data.